In keeping with the well established prognostic role of tumor proliferation in HR+ BC, we hypothesized that low baseline levels of TK1 might identify a sub-group of patients with HR+ MBC with extended clinical benefit while on ET. The gene discussed is TK1; the disease is breast cancer.